Skip to main content
. 2023 Mar 27;19(3):e1010678. doi: 10.1371/journal.pgen.1010678

Fig 3. Functional validation of the ability of CYP6P9a/b to confer resistance to carbamates.

Fig 3

A) Determination of cytochrome P450 reductase activity using a model substrate, cytochrome c. All results are average of three replicates ± standard error of the means. B) Metabolic activities of the recombinant An. funestus CYP6P9a and CYP6P9b. Depletion of 20 μM bendiocarb in metabolic assays with recombinant CYP6P9a and–b (SEM = 3). C) Transgenic expression of CYP6P9a/b in Drosophila melanogaster using the GAL4/UAS system. The observed mortality pattern of GAL4 x UAS-CYP6P9a and GAL4 x UAS-CYP6P9b flies exposed to 0.007% bendiocarb. D) The relative expression of the CYP6P9a and b transgenes in transgenic D. melanogaster Act5C-CYP6P9a/b strains and the control sample with no transgene expression. The data shown are the mean ± SEM (n = 3).